What are the risks of compounded semaglutide
Placebo participants, meanwhile, were eating about as much as they had at the start of the study by week 60, or slightly more, and their weight started creeping back up after week 40
Among commercially insured non-diabetic individuals with obesity, people who identified as female, received point-of-service or preferred provider organization insurance coverage, and who took medications such as antidepressants or thyroid or hormone medications, were more likely to begin taking semaglutide compared to people who identified as males, or those who were covered by health management organization or exclusive provider organization plans
By preregistering detailed protocols with contemporaneously documented amendments, we ensured methodological transparency
It was first approved by the US Food and Drug Administration (FDA) in 2017